Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health (R01CA134777, R01CA173852, R01HL140961, R01HL146137)
  • National Cancer Institute (1U54CA196519)
  • V Foundation for Cancer Research
  • Riley Children's Foundation

This publication has 63 references indexed in Scilit: